Background
Heart failure with preserved ejection fraction (HFPEF) carries significant mortality and morbidity. This population is characterized by marked heterogeneity. To date, this population has been poorly phenotyped and it remains unclear what proportion may have evidence of myocardial infarction (MI), undiagnosed cardiomyopathies or phenocopies of heart failure. At present, echocardiography remains the primary modality for diagnosis and inclusion into randomized controlled trials but can be challenging due to the high prevalence of lung disease, obesity and frailty. We sought to evaluate the impact of adding cardiac magnetic resonance imaging (CMR) to the diagnostic pathway.
Methods
CMR was offered as part of DIAMOND-HFPEF (Developing Imaging And plasMa biOmarkers iN Describing Heart Failure with Preserved Ejection Fraction): a prospective, observational, cohort study. Inclusion criteria were: clinical features of HF and left ventricular ejection fraction (LVEF) > 50% as per echocardiography. Exclusion criteria were: suspected or confirmed cardiomyopathy, pericardial constriction, inability to consent, noncardiovascular life expectancy < 6 months, myocardial infarction in the preceding 6 months, severe valve disease, severe obstructive pulmonary disease (or FEV 1 < 30% or FVC < 50% predicted) and estimated glomerular filtration rate < 30 ml/min/m 2 . 138 eligible subjects underwent 3 T CMR (Siemens Skyra) according to a 1 Cardiovascular sciences, NIHR Cardiovascular BRU, University of Leicester, Leicester, UK 
Results
Baseline clinical and CMR data are summarized in Table  1 . Qualitative analyses revealed new diagnoses of (see Figure 1 ): 'silent' myocardial infarction (n = 13), hypertrophic cardiomyopathy (definite [n = 4], probable [3], possible [n =1]), pericardial constriction (n = 5) and amyloid (n = 2). Perfusion imaging revealed reversible inducible ischaemia in 27 patients, of which 11 were likely to be secondary to microvascular dysfunction. Late gadolinium imaging revealed mid-wall focal fibrosis in 33 patients and insertion point fibrosis in 24 patients.
Conclusions
CMR provides unique insights into etiology, enabling disease-specific management and the potential for tailored therapies to improve outcomes in HFPEF. Furthermore, the frequent finding of HFPEF 'phenocopies' such as hypertrophic cardiomyopathy and amyloid in our cohort may in part explain the limited efficacy of generic medical therapies in numerous randomized controlled studies.
